The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

Zepbound is the name of the first drug approved by the FDA for obstructive sleep apnea. According to the Mayo Clinic, obstructive sleep apnea is a common sleep-related breathing disorder that ...

An insurer’s decision to delay reimbursement of drugs licensed under the Food and Drug Administration’s accelerated approval program has sparked controversy. Independence Blue Cross’s ...

By Gina Kolata The Food and Drug Administration approved a new medication Thursday to treat pain from an injury or surgery. It is expensive, with a list price of $15.50 per pill. But unlike opioid ...

APhA, in a formal comment letter, reiterated its concerns with FDA's list of drugs that present demonstrable difficulties for compounding. APhA's concerns include the agency's decision to identify ...

Around 40,000 people in the US, both children and adults, live with NF1-PN. Image credit: Shutterstock / AimPix. The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...

Resources used to select the drug name pairs targeted for tall man letters included the ISMP list of name pairs with recommended tall man letters (63%), the FDA-approved list of name pairs with ...

the FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief. The drug, suzetrigine, received FDA approval on ...

The new drug joins UCB’s recently FDA-approved FcRn-targeting antibody Rystiggo (rozanolixizumab), which got the nod from the US regulator in June for gMG patients who are either AChR or anti ...

The FDA has approved Samsung Bioepis’ biosimilars of Amgen’s Prolia and Xgeva and granted the therapies interchangeability designation. No information is available on when the drugs will launch or on ...